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Lysine-specific demethylase 1 (LSD1) was recently identified as the
first histone demethylase that specifically demethylates mono-
methylated and dimethylated histone H3 at K4. It is a component
of the CoREST and other corepressor complexes and plays an
important role in silencing neuronal-specific genes in nonneuronal
cells, but the molecular mechanisms of its action remain unclear.
The 2.8-Å-resolution crystal structure of the human LSD1 reveals
that LSD1 defines a new subfamily of FAD-dependent oxidases.
The active center of LSD1 is characterized by a remarkable 1,245-Å3
substrate-binding cavity with a highly negative electrostatic po-
tential. Although the protein core of LSD1 resembles other fla-
voenzymes, its enzymatic activity and functions require two ad-
ditional structural modules: an N-terminal SWIRM domain
important for protein stability and a large insertion in the catalytic
domain indispensable both for the demethylase activity and the
interaction with CoREST. These results provide a framework for
further probing the catalytic mechanism and the functional roles of
LSD1.
histone modification  flavoenzyme  catalysis
H istone proteins are subject to a variety of posttranslationalmodifications, including acetylation, methylation, phosphory-
lation, and ubiquitination, and it is these histone modifications that
function as the molecular switches that alter the state of compaction
of chromatin to allow gene activation or repression (1–3). Some
histone modifications (e.g., acetylation and phosphorylation) are
highly dynamic, whereas others (e.g., methylation) have been
regarded as ‘‘permanent’’ chromatin marks. However, the discov-
eries of lysine-specific demethylase 1 (LSD1) and jumonji domain
C (JmjC) domain-containing histone demethylase 1 (JHDM1) have
changed this picture (4, 5). Shi and colleagues demonstrated that
LSD1 is a histone lysine demethylase that specifically demethylates
monomethylated and dimethylated histone H3 at K4 (4). More
recently, we and others have shown that many JmjC domain-
containing proteins are capable of demethylating dimethylated and
trimethylated histone proteins (4–10). These findings suggest that
histone methylation is a reversible modification and can be regu-
lated under similar enzymatic control as other histone modifica-
tions (11–13).
LSD1 is a component of a number of transcriptional corepressor
complexes, such as CoREST, CtBP, and HDAC complexes, and
plays an important role in silencing neuronal-specific genes in
nonneuronal cells (14–19). The C-terminal two-thirds of LSD1
contains an amine oxidase-like (AOL) domain, which shares ex-
tensive sequence homology to FAD-dependent oxidases (Fig. 1 A
and C) (20–22). In addition, LSD1 also contains an N-terminal
SWIRM domain (Fig. 1A), which has been recently identified as a
conserved motif often found in chromatin remodeling and modi-
fying complexes with unknown function (23). Recent studies sug-
gest that the specificity and activity of LSD1 can be modulated by
its interacting factors (4, 24–26). However, the molecular mecha-
nism by which this regulation is achieved remains unclear.
Here we report the crystal structure of LSD1 at 2.8-Å resolution
(Fig. 1). The x-ray analysis reveals that the overall structure of LSD1
closely resembles those of flavin-dependent oxidases (22) and
contains a marked large catalytic cavity with a highly negative
electrostatic potential. We further demonstrate that a large inser-
tion in the catalytic domain is indispensable both for the demeth-
ylase activity of LSD1 and the interaction between LSD1 and
CoREST.
Results
The Overall Structure of LSD1. A recombinant protein of human
LSD1 with an N-terminal deletion, LSD1N (residues 172–833)
(Fig. 1 A), was prepared by overexpression and purification from
Escherichia coli. LSD1N was chosen for structural study be-
cause the N-terminal region of LSD1 was confirmed to be
dispensable for LSD1 activity and is an unstructured region (27).
For simplicity, we hereafter use LSD1 to represent LSD1N
unless stated otherwise. The purified LSD1 was crystallized in
space group P6122, and the structure was determined by multi-
wavelength anomalous dispersion method. The crystallographic
refinement resulted in a model with Rwork and Rfree values of
23.0% and 28.3%, respectively (Table 1, which is published as
supporting information on the PNAS web site).
The structure of LSD1 contains three domains. Two of them,
the SWIRM (residues 172–270) and AOL (residues 271–417 and
523–833) domains, pack together through extensive interactions
resulting in a globular structure (Fig. 1 A and B). The SWIRM
domain consists mostly of -helices and is a newly identified
structural module often found in chromatin-associated proteins
(Fig. 1 B and C) (28–30). The AOL domain folds into a compact
structure that exhibits a topology found in several f lavin-
dependent oxidases (Fig. 1B) (22, 31). The AOL domain con-
tains a large insertion (residues 418–522) that forms an addi-
tional domain and adopts a tower-like structure (Tower domain)
protruding away from the AOL domain by 75 Å (Fig. 1 B and C).
The Tower consists of a pair of long helices that adopts a typical
antiparallel coiled-coil conformation (Fig. 1C).
The SWIRM Domain. The SWIRM domain of LSD1 reveals a
six-helical bundle architecture characterized by a long helix, SW4,
in the center surrounded by five other helices (Fig. 2A). One unique
feature of the LSD1 SWIRM domain is an additional two-stranded
-sheet formed between the SW4–SW5 loop and the C terminus
of the SWIRM domain (Figs. 1C and 2A). This short -sheet helps
anchor the interactions between the SWIRM and AOL domains by
forcing the SW6–SW2 loop to protrude out into a hydrophobic
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pocket formed by helices F1, F2, F3, and F8 of the AOL
domain (Fig. 2B). The LSD1 SWIRM domain is structurally most
similar to those of the chromatin-remodeling proteins Swi3 and
ADA2 (Fig. 2 C and D). The three SWIRM domains have very
similar hydrophobic core packings. The differences among the
three structures are primarily confined to SW1 and SW2, which
are not conserved and are positioned further away from the
hydrophobic core (Fig. 2 C and D).
The SWIRM–AOL Domain Interaction. The SWIRM domain packs
closely against the AOL domain and is located far away from both
the FAD-binding site and the catalytic center of LSD1 (Fig. 1B). A
three-amino-acid motif (F264G265I266) between SW6 and SW2
anchors the binding through extensive interactions with the AOL
domain, involving both hydrophobic contacts and hydrogen-
bonding interactions (Fig. 2B). The side chains of F264 and I266
and the main chain C atom of G265 stack against a hydrophobic
pocket from the AOL domain. These hydrophobic contacts are
buttressed by extensive hydrogen-bonding interactions between the
backbone of this tri-residue motif and the side chains of R295 and
Q348. The SWIRM–AOL packing buries a total surface area of
1,115 Å2, and the residues that form the interface are highly
conserved across species (Fig. 1C). Based on these observations, we
conclude that the prearrangement of the SWIRM and AOL
domains is important for LSD1 protein functions. Although the
SWIRM domain can be expressed as a separate protein with native
Fig. 1. Overview of the LSD1 structure. (A) Domain organization of LSD1. The SWIRM domain is shown in green, the AOL domain is in blue (the FAD-binding
subdomain) and cyan (the substrate-binding subdomain), and the Tower domain is in yellow. The N-terminal flexible region and the C-terminal tail that are not
included in the structure determination are colored in gray. (B) Ribbon diagram of the LSD1 structure. The molecule is colored as in A. FAD is in ball-and-stick
representation and is colored in red. (C) Structural-based sequence alignments of the SWIRM and AOL domains of LSD1 and its homologs. Secondary structure
assignments from the LSD1 crystal structure are shown as cylinders (-helices) and arrows (-strands) above the aligned sequences and colored as in B.








conformation (28), efforts to prepare the AOL and Tower domains
of LSD1 yielded insoluble protein (data not shown), suggesting that
it requires an interface with the SWIRM domain for stability.
The AOL Domain. The AOL domain of LSD1 folds into two well
defined subdomains, an FAD-binding subdomain and a substrate-
binding subdomain, with their sequences intermingled together
(Figs. 1C and 3A). The FAD-binding subdomain has three frag-
ments (residues 271–356, 559–657, and 770–833) and adopts a
mixed – structure (Fig. 3A). As is evident from the high degree
of sequence conservation, the binding mode and the conformation
of the FAD in the LSD1 structure closely resemble those observed
in the enzymes sharing the dinucleotide-binding fold (Fig. 6, which
is published as supporting information on the PNAS web site) (22,
32–34). The substrate-binding subdomain comprises three frag-
ments (residues 357–417, 523–558, and 658–769) and is character-
ized by a six-stranded mixed -sheet flanked by six -helices (Fig.
3A). The two subdomains create a big cavity that defines the
enzyme activity center at their interface (Fig. 3 A and C).
The AOL domain of LSD1 is most similar to the structure of
maize polyamine oxidase (PAO). The two structures can be super-
imposed with a 2.9-Å rmsd in the positions of 419 of 462 C atoms
(Figs. 1C and 3B). Although the similarity is evident in the
FAD-binding subdomain, the structure of LSD1 substrate-binding
subdomain differs from that of PAO in several aspects. First, LSD1
comprises a long insertion between S2 and S3 compared with
PAO (Fig. 3B). Second, LSD1 contains a large catalytic cavity
between the FAD- and substrate-binding subdomains with a vol-
ume of 1,245 Å3 (Figs. 3C and 4A). In contrast, the catalytic center
of PAO is located in a narrow U-shaped tunnel with a significantly
smaller volume (716 Å3) (32, 35). The difference in the shape of the
substrate-binding site reflects the different substrate specificities of
the two enzymes; the substrates of LSD1 are methylated histone
peptides, which are bulkier than the linear-shaped substrates of
PAO, like spermidine (35). Taken together, these data reinforce the
conclusion that, although PAO and the AOL domain of LSD1 share
a similar overall folding topology, LSD1 defines a new subfamily of
FAD-dependent oxidases with unique substrate specificity (4).
The Catalytic Center. The catalytic center of LSD1 consists of a
remarkable large cavity that occupies the center of the AOL
domain at the interface between the substrate- and FAD-binding
subdomains (Fig. 4A). The cavity is framed by many structural
elements that surround the catalytic center; a six-stranded -sheet
(S1 and S6–S9) and a long helix (S3) form the left side and
the bottom surfaces, respectively, whereas a short one-turn helix
(S4), a two-stranded -sheet (F5–F7), and several loops with
variable lengths cover the rest of the cavity (Fig. 4A). There is a
marked contrast in the chemical nature of different areas on the
inner surface of the catalytic cavity. The left side is a flat surface
Fig. 2. The structure of SWIRM domain and its interactions with the AOL
domain. (A) Ribbon diagram of the SWIRM domain. (B) A three-amino-acid
motif (F264G265I266) of the SWIRM domain mediates the interactions be-
tween the SWIRM and AOL domains. The SWIRM and AOL domains are
colored in green and blue, respectively. Side chains of residues important for
the interactions are shown explicitly. The hydrogen bonds are shown as
dotted purple lines. (C and D) Superposition of the LSD1 SWIRM domain
(green) with those of Swi3 (red) and Ada2 (blue).
Fig. 3. The structure of the AOL domain. (A) Stereo ribbon diagram of the
AOL domain of LSD1. The molecule is colored as in Fig. 1B. The FAD is in
ball-and-stick representation with carbon colored yellow, nitrogen colored
blue, oxygen colored red, and phosphorus colored orange. (B) Superposition
of LSD1 (the AOL and the Tower domains) on the structure of PAO. LSD1 is in
cyan, and PAO is in blue. The Tower domain of LSD1 is colored in yellow. (C)
Superposition of the AOL domain of LSD1 on the structure of PAO highlight-
ing the differences in the catalytic cavity. LSD1 is in cyan and purple, and PAO
is in blue and orange. The Tower domain of LSD1 is colored in yellow. The FAD,
in red and ball-and-stick representation, lies in the back of the cavity. The
positional change of three -helices (S1, S2, and S4) of PAO relative to
those of LSD1 significantly reduces the volume of the catalytic cavity.
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and is lined mainly by hydrophobic residues (Fig. 4 A and B). In
contrast, the right side of the cavity presents mostly the acidic side
chains and the backbone carbonyl oxygen atoms on the concave-
shaped surface (Fig. 4 A and B). Notably, point mutations of the
residues on both sides of the cavity abolished the LSD1 demethylase
activity (Fig. 4D). The cavity goes deep into the protein, extending
for a length of 23 Å from its entrance to the core of the catalytic
site where the flavin ring is located. K661 is a crucial element
characterizing the innermost section of the catalytic center (Fig.
4A). It is hydrogen-bonded to the N5 atom of the FAD via a
conserved water molecule (Fig. 4A). The fact that a point mutation,
K661A, completely abolished the demethylation activity of LSD1
suggests that K661 plays an essential role in flavin reduction as its
counterpart, K300, in the case of PAO (25, 36).
Compared with other flavin-dependent oxidases, LSD1 has
another unique structural feature: the two diagonally interacting
helices, S1 and S3, form a highly acidic flat surface at the
entrance of the catalytic cavity, serving as an additional binding site
for the basic histone H3 tail (Fig. 4 A and C). Most of the residues
forming this surface and the catalytic cavity are highly conserved
not only among LSD1 orthologs in different species but also in
LSD2, a close homolog of LSD1 (Fig. 1C) (4). Thus, it is likely that
LSD2 also contains a similar catalytic center with a large cavity.
This finding is consistent with the observation that the two proteins
share the same substrate specificity (unpublished data).
The Tower Domain Contains an Antiparallel Coiled Coil and Is Indis-
pensable for the Demethylase Activity of LSD1. The overall structure
of the LSD1 Tower domain is a typical antiparallel coiled coil,
with two extended -helices (T1 and T2) that pack together
in a left-handed superhelix (Figs. 1B and 5A). T1 is the
extension of helix S2 of the AOL domain (Figs. 1B and 3A). The
sequence of the Tower domain reveals a repeating pattern of
seven residues, (abcdefg)n, the characteristic of coiled-coil pro-
teins, with hydrophobic amino acids predominating at positions
a and d of the heptad repeat (Fig. 5A) (37).
The Tower protrudes from the catalytic center of LSD1 and
makes no obvious contact with the rest of the protein (Fig. 1B). This
arrangement raises the question of whether the Tower domain plays
a role in the histone demethylase activity. To address this issue, a
deletion mutant of LSD1 (LSD1Tower), in which the Tower
domain was deleted and replaced by a pentaglycine loop, was
expressed and purified from E. coli (Fig. 5B). LSD1 was able to
reduce the methylation level at K4, whereas LSD1Tower failed to
do so even at a much higher protein concentration (Fig. 5C and data
not shown). An effect of this deletion mutation on the structural
stability was ruled out, owing to the fact that its biophysical and
structural properties are similar to those of the wild-type LSD1
protein as assessed by gel-filtration chromatography analysis (data
not shown). These results support the notion that the Tower domain
is indispensable for the histone demethylase activity of LSD1.
The Tower Domain Mediates the Interaction Between LSD1 and
CoREST. Besides being important for the LSD1 demethylase
activity, the Tower domain of LSD1 may also act as an adaptor
to recruit other proteins. LSD1 was identified as a component
of the putative LSD1 complex containing HDAC12, CtBP1,
CoREST, HBC80, and BRAF35, among others (17, 25). Grow-
ing evidence showed that LSD1-interacting proteins regulate its
activity and substrate specificity (24–26). One of these proteins,
CoREST, endows LSD1 with the ability to demethylate nucleo-
somal substrates and protects LSD1 from proteasomal degra-
dation (24, 25). We investigated the interaction of a His-tagged
C-terminal fragment of CoREST (residues 293–482) with two
complementary deletion mutants of LSD1, LSD1Tower, and
LSD1-Tower (amino acids 420–520) employing a pull-down
assay (Fig. 5 B and D). We were surprised to find that the Tower
domain of LSD1 is, by itself, sufficient for a stable interaction
with CoREST-C, forming complexes that can survive extensive
washing (Fig. 5D). The fact that LSD1Tower does not interact
with CoREST indicates that the SWIRM and AOL domains of
LSD1 do not significantly contribute to the interaction with
CoREST (Fig. 5D). Based on these results, we conclude that the
Tower domain of LSD1 contains the binding site for CoREST.
Discussion
The Functions of the SWIRM Domain. Although both structure and
biochemical data presented here indicate that the SWIRM domain
is important for the stability of LSD1, the function of the SWIRM
domain in LSD1 has not been established yet. Both the Swi3 and
Ada2 SWIRM domains are able to interact with double-stranded
DNAs nonspecifically, and these interactions are important for the
in vivo functions of Swi3 and Ada2 (29, 30). These findings led us
to hypothesize that the LSD1 SWIRM domain might also be
capable of binding nucleic acids. However, the gel-mobility shift
assay clearly demonstrated that the SWIRM domain of LSD1 did
not shift DNA even at a very high protein concentration, indicating
that the LSD1 SWIRM domain is not a DNA-binding motif (data
not shown). A recent study showed that the SWIRM domain of
LSD1 may interact with the N-terminal tail of histone H3 (28–30).
Particularly, an H3 peptide bearing two point mutations (R8E
T11K) weakened the interaction between the SWIRM domain and
the peptide (30). However, close examination of our crystal struc-
ture of LSD1 revealed that the SWIRM domain is too far away from
Fig. 4. The catalytic center of LSD1. (A) Stereo ribbon diagram of the catalytic
center of LSD1. The LSD1 and FAD are colored as in Fig. 3A. The modeled C
atom (green sphere) is located 3.6 Å from the N5 atom of the FAD. The side
chain of the catalytically important K661 is shown in ball-and-stick represen-
tation. The conserved water molecule, which makes hydrogen-bonding inter-
actions with both K661 and FAD, is shown as a red sphere. The hydrogen-
bonding interactions are represented by dotted purple lines. Also highlighted
are the side chains of the residues that may be involved in substrate recogni-
tion. (B) Electrostatic surface representation of the substrate-binding pocket.
The view is the same as in A. The 3D coordination system denotes the
orientation relative to that in C. (C) Electrostatic surface representation of
LSD1 shows an acidic surface formed by helices S1 and S3 at the entrance of
the catalytic cavity. The 3D coordination system denotes the orientation
relative to that in B. (D) Histone demethylase activity assay of LSD1 and its
mutants. Approximately equal amounts (2 g) of wild-type and mutant
recombinant LSD1 were incubated with equal amounts of 3H-labeled H3K4
methylated substrates. Released 3H-formaldehyde from each reaction was
quantified by scintillation counting (cpm).








the catalytic center of LSD1 (24 Å). Without large conforma-
tional change in LSD1, it is unlikely that a histone H3 tail binds to
LSD1 with its K4 located at the catalytic center and R8T11
interacting with the SWIRM domain simultaneously. More bio-
chemical and structural studies are needed to resolve this discrep-
ancy and to better understand the functions of the SWIRM domain
in LSD1.
The Functions of the Tower Domain. The Tower domain directly
interacts with one of the LSD1-interacting proteins, CoREST (Fig.
5D). The two SANT domains of CoREST have been proposed to
be a histone-tail-presenting module (38). Consistent with this
model, the SANT2 domain of CoREST was shown to play a key role
in endowing LSD1 with the ability to demethylate nucleosomal
substrates (24). Thus, the Tower domain of LSD1, together with the
CoREST SANT2 domain, functions as a molecular bridge that
connects LSD1 to its nucleosomal substrates.
In addition to mediating the interaction with CoREST, we also
found that the Tower domain is indispensable for the histone
demethylase activity of LSD1 (Fig. 5C). But how does the Tower
domain affect the activity of LSD1 without direct interactions with
the catalytic center? One possible mechanism is that the Tower may
play a role in substrate binding. Alternatively, the involvement of
the Tower domain on the LSD1 enzymatic activity could be due to
an allosteric effect. That is, in the presence of the methylated
histone substrate, the Tower domain induces some conformational
changes in LSD1 that transform the catalytic center into an active
conformation.
Implications for the Substrate Binding Mechanism. So far, the precise
mechanism by which LSD1 recognizes the histone peptide sub-
strates and catalyzes histone demethylation remains unknown. In
this respect, the crystal structure of LSD1 reported here reveals
several unique features of LSD1. First, structural comparison of
flavoproteins that carry out dehydrogenation reactions has revealed
that the substrate carbon atom that undergoes flavin-dependent
oxidation binds in a highly conserved position in front of the flavin
N5-C4a locus, indicating that the substrate carbon atom of a
flavoenzyme could be accurately located in its structure (22). On
this basis, the C atom of a methylated lysine was modeled in the
catalytic site of LSD1 (Fig. 4A). The distance between the C atom
and the protein surface is 21 Å. It is unlikely that a histone peptide
adopting an extended conformation would bind to LSD1 with its
methylated lysine residue positioned in the catalytic center. Thus,
we conclude that the histone peptide must enter the catalytic cavity
and fold into certain unique conformation to position the methyl-
ated lysine residue in the correct location for catalysis. Second, the
opening of the catalytic cavity is characterized by several highly
conserved solvent-accessible glutamate and aspartate residues (Fig.
4 A and D), which seem to be suited to fulfilling the role of
interacting with the basic residues of the histone peptide. Third, the
catalytic cavity of LSD1 can accommodate at most a 10-residue
polypeptide, which is shorter than the minimum length (16 and
21) of the histone H3 peptide required for the substrate recog-
nition by LSD1 (27). These structural features lead us to suggest
that the acidic surface formed by helices S1 and S3 (Fig. 4C) at
the entrance of the catalytic center makes additional sequence-
specific interactions with the H3 peptide. Based on these observa-
tions, we propose a model of substrate binding by LSD1 in which
the methylated histone H3 tail adopts a loop-like structure so that
the methylated K4 is positioned at the catalytic center and the
negative charged residues (for instance, R8 and K9) of the H3
peptide make sequence-specific contacts with the acidic residues of
LSD1 both inside and outside of the catalytic cavity (Fig. 4).
Although our proposed substrate-binding mechanism is plausible
based on the LSD1 crystal structure and current biochemical data,
additional structural studies of LSD1 complexed with peptide
substrates and other interacting proteins are essential to verify this
model and to clarify the catalytic and regulatory mechanisms of
histone demethylation by LSD1.
Materials and Methods
Cloning, Expression, and Purification. An N-terminal deleted human
LSD1 (residues 172–834) was expressed in E. coli BL21(DE3) by
using a modified pET28b vector with a SUMO protein fused at the
N terminus after the 6His tag. The SUMO moiety of the vector
Fig. 5. The Tower domain of LSD1 is an
antiparallel coiled coil and is indispensable
for both the demethylase activity and the
interaction between LSD1 and CoREST. (A)
Ribbon diagram of the coiled coil of the
Tower domain. The amino acids at the d
positions of the heptad repeat of the two
helices are in space-filling representation
and colored in red (T1) and purple (T2),
respectively. (B) Schematic diagrams of
LSD1 and the LSD1 deletion mutants. The
domains are colored as in Fig. 1A. (C) His-
tone demethylase activity assay of LSD1
and its deletion mutant LSD1Tower. Ap-
proximately equal amounts (2 g) of wild-
type and mutant recombinant LSD1
(Lower) were incubated with equal
amounts of 3H-labeled H3K4 methylated
substrates. Released 3H-formaldehyde
from each reaction was quantified by scin-
tillation counting (cpm) (Upper). (D) The
Tower domain of LSD1 interacts with CoR-
EST. Comparable wild-type and deletion
mutants of LSD1 were incubated with Ni2
beads in the presence or absence of His-
SUMO-CoREST-C. The bound proteins
(Middle) and the flow-through proteins
(Bottom) were analyzed by SDSPAGE. The input proteins are shown in Top. The asterisks in Middle indicate the bound LSD1 and LSD1-Tower, and the diamonds
in Bottom indicate the unbound LSD1 (lane 7) and LSD1 mutants (lanes 5 and 6) after incubation with His-SUMO-CoREST-C. LSD1-Tower did not bind the Ni2
beads (no LSD1-Tower band in Middle). The crosses indicate the nonspecifically bound LSD1 and LSD1Tower (lanes 3, 4, and 6 in Middle). The arrows indicate
two degradation products of the His-SUMO-CoREST-C protein.
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helped the expressed fusion proteins in a soluble native form. The
His-SUMO-LSD1 protein was purified by Ni-NTA affinity column
following standard procedures. Then the ULP1 protease was added
to remove the His-SUMO tag. The LSD1 protein was further
purified by gel-filtration chromatography. The LSD1 mutants and
the C-terminal fragment of CoREST (CoREST-C) were cloned,
expressed, and purified following the same procedures as described
above.
Crystallization and Data Collection. Crystals were grown by hanging-
drop vapor diffusion against 5% PEG 8000, 150 mM NaCl, 10 mM
MgCl2, and 50 mM Na2HPO4KH2PO4 (pH 6.33). They are in
space group P6122 (a  b  187.11 Å; c  106.58 Å) with one LSD1
molecule per asymmetric unit. For preparation of a mercury
derivative, crystals were transferred gradually into 25% PEG 8000,
150 mM NaCl, 10 mM MgCl2, 50 mM Mes (pH 6.3), and 0.5 mM
FAD and soaked in this buffer with 0.1 mM added HgAc2. Both
native and derivative crystals were transferred stepwise into a
stabilizing solution containing 30% PEG 8000, 25% glycerol, 150
mM NaCl, 10 mM MgCl2, 50 mM Na2HPO4KH2PO4 (pH 6.33),
and 0.5 mM FAD. The crystals were flash-frozen by immersion in
liquid nitrogen. Diffraction data were collected at Advanced Pho-
ton Source beamline 23-ID. Data were integrated and scaled by
using the program HKL2000 (Table 1) (39).
Structure Determination and Refinement. Multiwavelength anoma-
lous dispersion data from the mercury derivative were used to
obtain initial phases. Three mercury atoms were located and
refined, and the multiwavelength anomalous dispersion phases
were calculated by using SHARP (40); the initial multiwavelength
anomalous dispersion map was significantly improved by solvent
flattening, which allowed us to fit a model of the maize PAO
structure (Protein Data Bank ID code 1B37) as a rigid body. From
this initial model, another round of density modification led to a
clear and completely interpretable map. A model of the relevant
residues of human LSD1 was built into the density by using the
program O (41); the model was then transferred into the native unit
cell by rigid-body refinement and further refined by using simulated
annealing and positional refinement in CNS (42) with manual
rebuilding using O.
Histone Demethylase Assay. The histone demethylase assay was
performed essentially as previously described (5). Briefly, core
histone substrates methylated by GST-SET7 in the presence of
3H-SAM were incubated with wild-type or mutant recombinant
LSD1 in histone demethylation buffer (100 mM glycine, pH 91
mM PMSF1 mM DTT50 mM KCl) at 37°C for 1 h. For
detection of the released 3H-formaldehyde, a modified NASH
method (43) was used. After trichloroacetic acid precipitation,
an equal volume of NASH reagent (3.89 M ammonium acetate,
0.1 M acetic acid, and 0.2% 2,4-pentanedione) was added into
the supernatant, and the mixtures were incubated at 37°C for 50
min before extraction with equal volume of 1-pentanol. The
extracted radioactivity was measured by scintillation counting.
His-Tag Pull-Down Assay. A total of 10 g of purified His-SUMO-
CoREST-C (residues 293–482) protein was incubated with 20 g
of LSD1, 18 g of LSD1Tower, or 4 g of LSD1-Tower,
respectively, at 4°C for 16 h in 40 l of binding buffer (25 mM
TrisHCl, pH 8.0300 mM NaCl3 mM imidazole) containing 5
l of Ni2-NTA beads. The beads were then washed three times
by 100 l of binding buffer and finally resuspended in 20 l of
2 SDS protein sample buffer. The samples of the input, beads,
and flow-through were analyzed by SDSPAGE. The His-
SUMO tag itself did not interact with LSD1.
Illustrations. Figures were prepared by using the programs
PyMOL (http:pymol.sourceforge.net) and GRASP (44).
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